Precede Biosciences

Boston, MA · Founded 2021 · Privately Held (backing)

Developer of a liquid biopsy platform designed to provide resolution into disease-defining biology from a blood test. Precede Biosciences is based in Boston, MA and was founded in 2021. Its last reported valuation was $199 million in Oct 2025. It has raised $132 million.

Last reported valuation
$198.5M
Oct 2026
Priced at
—
Total raised
$132.0M
Last round
—

Who backs Precede Biosciences?

17 investors
InvestorType
Alexandria Venture InvestmentsOther
Mirae Asset CapitalVenture capital
Qatar Investment AuthorityAsset manager
Osage University PartnersVenture capital
Labcorp Venture FundVenture capital
Bristol-Myers Squibb—
UPMC EnterprisesVenture capital
Illumina VenturesVenture capital
5AM VenturesPE / buyout
Lilly Asia VenturesVenture capital
+ 7 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Precede Biosciences investors

17 investors are on record for Precede Biosciences, including Alexandria Venture Investments, Mirae Asset Capital, Qatar Investment Authority and Osage University Partners. By type, the record holds 6 venture capital firms, 1 asset manager and 1 private equity firm.

Free account
More of Precede Biosciences with a free account
  • ·The complete investor list: 17 names
  • ·Watch Precede Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 17 firms already write checks for companies like Precede Biosciences. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View